A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcinoma of the Bladder
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 20 May 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 20 May 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 20 May 2016 Status changed from not yet recruiting to recruiting.